Karunanithi, Sheelarani
Liu, Ruifu
Hou, Yongchun
Gonzalez, Giancarlo
Oldford, Natasha
Roe, Anne Jessica
Idipilly, Nethrie
Gupta, Kalpana
Amara, Chandra Sekhar
Putluri, Satwikreddy
Lee, Grace Kyueun
Valentin-Goyco, Juan
Stetson, Lindsay
Moreton, Stephen A.
Putluri, Vasanta
Kavuri, Shyam M. http://orcid.org/0000-0002-3321-6727
Saunthararajah, Yogen http://orcid.org/0000-0002-9757-1031
de Lima, Marcos
Tochtrop, Gregory P.
Putluri, Nagireddy
Wald, David N. http://orcid.org/0000-0002-8695-1178
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R43CA22870, R43CA22870, R43CA22870, R01CA220297, R01CA216426)
U.S. Department of Veterans Affairs (I01 BX004995-01A1)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
American Cancer Society (127430-RSG-15-105-01-CNE)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Defense (W81XWH-18-1-0035, W81XWH-18-1-0084)
Article History
Received: 25 September 2019
Revised: 20 May 2021
Accepted: 24 June 2021
First Online: 8 July 2021
Competing interests
: DNW is an inventor on patents related to S-250 and his employer Case Western Reserve University is the owner of patents related to S-250. SMK is a stakeholder in NeoZenome Therapeutics Inc. No other authors have any conflicts of interest with this study.